Macrolide resistance of Mycoplasma pneumoniae in several regions of China from 2013 to 2019
Yue Jiang,Haiwei Dou,Bo Xu,Baoping Xu,Wei Zhou,Hong Wang,Lixia Ge,Yinghui Hu,Xiaohua Han,Xuanguang Qin,Jing Li,Leping Ye,Liqun Wu,Huimin Zuo,Qi Zhang,Ling Liu,Wenjuan Hu,Junyan Shao,Qiaomian Yin,Lina Han,Xiaoyan Fu,Xiaopei Dong,Yan Dong,Yulin Fu,Mengmeng Zhao,Qing Sun,Jingwei Huo,Die Liu,Wenkao Liu,Yunjuan Li,Yang Wang,Deli Xin,Kunling Shen
DOI: https://doi.org/10.1017/S0950268824000323
2024-04-18
Abstract:This paper retrospectively analysed the prevalence of macrolide-resistant Mycoplasma pneumoniae (MRMP) in some parts of China. Between January 2013 and December 2019, we collected 4,145 respiratory samples, including pharyngeal swabs and alveolar lavage fluid. The highest PCR-positive rate of M. pneumoniae was 74.5% in Beijing, the highest resistance rate was 100% in Shanghai, and Gansu was the lowest with 20%. The highest PCR-positive rate of M. pneumoniae was 74.5% in 2013, and the highest MRMP was 97.4% in 2019; the PCR-positive rate of M. pneumoniae for adults in Beijing was 17.9% and the MRMP was 10.48%. Among the children diagnosed with community-acquired pneumonia (CAP), the PCR-positive and macrolide-resistant rates of M. pneumoniae were both higher in the severe ones. A2063G in domain V of 23S rRNA was the major macrolide-resistant mutation, accounting for more than 90%. The MIC values of all MRMP to erythromycin and azithromycin were ≥ 64 μg/ml, and the MICs of tetracycline and levofloxacin were ≤ 0.5 μg/ml and ≤ 1 μg/ml, respectively. The macrolide resistance varied in different regions and years. Among inpatients, the macrolide-resistant rate was higher in severe pneumonia. A2063G was the common mutation, and we found no resistance to tetracycline and levofloxacin.